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Abstract  
Background: Eastern Diamondback rattlesnake bites produce coagulopathy in the bite victims. The syndrome is treated 
with antivenom called Crotalidae Polyvalent Immune Fab. However following resolution of coagulopathy with the 
antidote, and sometimes days later, fibrinogen drops to very low levels. Rare bleeding may occur due to this recurrent 
defibrinogenation syndrome. No guidelines exist at this time of how these patients should be treated. However, many 
centers repeat the initial treatment protocol using another 6-18 vials of antidote acquiring significant treatment costs. 
Methods: We analyzed all cases treated at the University of Florida between 2013 and 2014 for the rattlesnake 
bites.  All cases were treated with Crotalidae Polyvalent Immune Fab as recommended per manufacturer 
recommendations upon initial presentation.  However, upon the recurrence of defibrinogenation, we administered the 
antivenom 1 vial diluted in 250 ml of normal saline and administered by continuous IV infusion over 2 to 12 hours 
tapered over 2 to 3 days. The patients and their coagulation labs were monitored at least daily during the recurrence of the 
defibrinogenation. 
Results: We identified 5 cases treated for Eastern Diamondback snake bites. All cases had recurrent defibrinogenation 
syndrome and treated as described above. All patients had normalization in their fibrinogen levels with the reinstitution 
of the antidote. Additionally, none of them had any further bleeding. No chills, fevers or cloudiness of solution reported 
during the continuous antidote administration. 
Conclusion: In our limited experience, administration of smaller doses of the antidote by continuous infusion was 
effective treatment for the recurrent defibrinogenation syndrome. The treatment did not produce significant treatment 
toxicities and was effective based on laboratory data and no reported bleeding. 
 
 
 
 
 
American Journal of Toxicology 
  
 
 
Ivy Union Publishing | http: //www.ivyunion.org June 15, 2015 | Volume 1, Issue 1 
Page 2 of 7 
Sliesoraitis S et al. American Journals of Toxicology 2015, 1:1-7 
7 
6 
 
Background 
About 50 to 60 proteinaceous substances comprise North American pit vipers’ venom, which evolved as 
ex vivo digestive aids. Each species’ venom contains a protein pattern unique to that species yet some 
proteins are shared among many or most pit viper venoms.(1,2) 
Some animals can develop immunity to these venoms by production of antibodies in the form of 
immunoglobulins. The immunoglobulins from these animals are harvested, purified, and manipulated into 
therapeutic antivenoms, which, when injected into humans, provide immunotherapy.  The antivenom 
neutralizes most but not all of the offending proteins in the event of envenomation.  
Sheep produce most of currently available antivenom by repeat inoculation of several species of snake 
venoms including the Eastern diamondback rattlesnake (Crotalus adamanteus), western diamondback 
rattlesnake (Crotalus atrox), Mojave rattlesnake (Crotalus scutulatus) and water moccasin (Agkistrodon 
piscivorus). After recovery of the immunoglobulins, the Fab fragments are modified from host IgG 
molecules by removal of the Fc component in order to minimize allergic reactions.  This ovine antibody 
is called Crotalidae Polyvalent Immune Fab (ovine) (CroFab®) (Protherics, Nashville TN, USA) and 
hereafter referred to as FabAV in this report. 
FabAV provides rescue from the majority of manifestations of envenomation syndrome elicited by 
bites of pit vipers native to the United States.  
The primary venom protein responsible for the characteristic coagulation perturbations by Eastern 
diamondback rattlesnakeis crotalase, the thrombin-like enzyme having alpha-fibrinogenase activity which 
causes incomplete lysis of fibrinogen. (3)  Fibrinogen is rapidly cleared from circulation upon 
envenomation, usually within 1-2 hours of envenomation.   Additionally,even trivial envenomation 
(4)can result in extreme hypofibrinogenemia to the extent that more global coagulation tests, such as 
prothrombin time (PT) and partial thromboplastin time (PTT) are rendered “nonclottable” despite the lack 
of perturbations in the proteins of the clotting cascade with the exception of near total lack of fibrinogen, 
which is manifested by nonclottable PTs and PTTs when the fibrinogen level falls to less than 
approximately 50mg/dL. (3)Additionally,FabAV rapidly curtails crotalaseactivity as evidenced by 
reversal of this extreme hypofibrinogenemia and normalization of subsequent PTs and PTTs within hours 
of its administration.   
Clinical investigation during the research and development phase of FabAV in premarketing studies 
discovered previously unappreciated recurrence syndromeusing a predetermined panel of laboratory 
studies.(5)  “Recurrence syndrome” is understood to be a late manifestation or reappearance of any 
manifestation of envenomation.  Recurrence as encountered clinically is primarily either extreme 
hypofibrinogenemia and/or thrombocytopenia occurring without evidence of any other recurrences of the 
envenomation syndrome, in that signs and symptoms such as pain, swelling, nausea, vomiting, 
hypotension, muscle fasciculation, and other symptoms are only rarely encountered following the 
administration of 6-18 vials of FabAV in the first 24-36 hours of treatment.(6)   
In the defibrinogenation recurrence syndrome, fibrinogen levels may drop from approximately normal 
levels to levels <50mg/dL as frequently as in 50% of patients who had been effectively treated with 
FabAV. Usually this is discovered 48-72 hours after the last infusion of FabAV.(5,7)  The PT and PTT 
typically appear prolonged, even “nonclottable,” as a reflection of this very low fibrinogen level.  Nearly 
all reports of this recurrence noticed the near total absence of return of any obvious or even subtle 
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hemorrhage which has caused considerable discussionregarding the importance or lack of importance of 
this “recurrence syndrome” as well as how to manage it. (6)  Indeed, it has been stated there is no 
standard of care how to, or even if, any therapeutic actions need to be taken upon discovery of evidence 
of the defibrinogenationrecurrence syndrome. (8)  On the other hand, Lavonis and colleagues (6) do 
report at least four cases in which hemorrhagic events occurred concurrently withthe reappearance of 
hypofibrinogenemia although causation cannot be directly incriminated. One case of fatal intracranial 
hemorrhage was reported from this institution. (9)  It remains unsettled whether hypofibrinogenemic 
recurrence is strictly a laboratory phenomenon or a meaningful clinical occurrence. 
This unexpected return of coagulopathy has caused many treaters, particularly those not experienced in 
this clinical situation, to assume that these findings represent a total collapse of control of the entire 
envenomation syndrome which results in their “starting over” with dosages and frequency of FabAV 
administration mirroring those used in their initial treatment.  With further experience, as outlined in 
several of these papers,(5-9)it was soon realized that even administration of small amounts of FabAV 
would quickly reverse the hypofibrinogenemia but whether that correction translates into in decreased 
hemorrhage as well as improved morbidity and mortality is as yet unknown. (5,6,9) 
In early 2013, we became aware of a report by Bush and colleagues (10) regarding their experience in 
treating five victims of hematologic recurrence syndrome (four with thrombocytopenia and one with 
hypofibrinogenemia) following initial control of the patient’s acute envenomation syndrome using 
high-dose bolus administration in the usual fashion. They reported using a much lower dose to address 
this recurrence syndrome using a continuous (as opposed to bolus) infusion.  This approach was rational 
because it allowed 1) titration of dose to match the observed effects; 2) allowing significantly fewertotal 
administered vials with subsequent decrease in antivenom exposure and well as savings in cost and 
arguably increased safety; and 3) this method directly addressed the putative pathophysiology supporting 
the concept of recurrence syndrome, namely that some 48-72 hours after the cessation of typicalinitial 
bolus treatment, small amounts of unbound venom are thought to percolate up from the wound and into 
the circulation at a time that there was no further circulating antivenom to neutralize these agents owing 
to the brief half-life of the FabAV. (5,11,12)  This notion requires that the amount of venom is too small 
to cause return of other signs and symptoms of the envenomation syndrome, yet even tiny amounts of 
unbound crotalase can rapidly produce severe hypofibrinogenemia that is easily reversed by continuous 
infusion of small amounts ofFabAV. 
Methods 
After communicating with these clinicians, we wished to employ this approach with several of the more 
severe Eastern diamondback rattlesnake envenomations we encounter.  We were aware of issues 
involving uncertainty of the sterility and stability of prepared FabAV solution but, having regularly and 
repeatedly witnessed reinstitution of massive doses of Fab using bolus administration by practitioners 
who thought this was a relapse of the entire envenomation syndrome, this new approach seemed to be 
more desirable.  Here we report our experience in treating patients severely envenomated by Eastern 
diamondback rattlesnakes as well assubstantiatingthose observations of Bush and colleagues. (11) 
We treated these five cases herein reported which represented the most severe envenomations by 
Eastern diamondback rattlesnakes in patients who were initially treated in (or soon transferred to) this 
institution over the warmer months of 2013 and 2014.  This method has not been used by us in less 
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severely envenomated patients bitten by Eastern diamondback rattlesnakes or even contemplated being 
used for victimsenvenomated by pygmy rattlesnakes or water moccasins.  Similarly, we did not 
preemptively use this method even in severe cases of envenomation prior to their development of 
recurrence syndrome with the possible exception of Cases 4 and 5, owing to our successes and experience 
gained by treating Cases 1-3.  However, we did employ this continual infusion of decreasing doses of 
FabAV once the recurrence was identified by the return of severe hypofibrinogenemia.  The FabAV was 
reconstituted with 250 ml of normal saline and administered by continuous infusion over 2 to 12 hour 
periods. In some instances, while dosage and frequency remained as ordered, pharmacy service insisted 
on a maximal 4-6 hr infusion time rather than a continual 12-24 hr infusion time.The doses were tapered 
over 2-3 day period. No solution cloudiness, fevers or chills were reported with longer infusions of the 
FabAV.  
At all times we believed that our actions were based on our understanding of the syndrome, the 
apparent high degree of efficacy of low-dose continuous infusion of FabAV, and all were done in what 
we held to be in the patients’ best interests.  This case series was approved by University of Florida IRB. 
Patients were contacted by phone and agreed to our reporting their results. Upon subject consent, each 
chart was reviewed for clinical events, laboratory date and outcomes as approved by the IRB. A total of 6 
patients were contacted and 5 consented to participate and are herein reported. 
Results 
Our results are presented in Table 1.  Figure 1 is a graphic display of events of Case 3 which is 
representative of the key events of all five cases.  The order in which these patients are reported in Table 
1 represent our growing experience over 2013 and 2014 which allowed and justified our progressively 
briefer and lower doses of constant infusion FabAV.  These successes resulted in our approach to Case 4 
in which we anticipated recurrence and greatly curtailed it using this method, and to Case 5, in which 
recurrence was aborted quickly as it was anticipated to be evolving.  Each of these two later cases 
received a total of only 6 vials over the last 3 days of treatment which in each case was on the first day of 
recurrence to receive 1 vial every 8 hours; on the second day, 1 vial every 12 hours; and on the third and 
last day, 1 vial over 24 hours, after which the fibrinogen level was followed for a day or so in order to 
warrant discharge. 
All five patients were confirmed to have been envenomated by Eastern diamondback rattlesnakes.  
Note that four of these five patients were bitten in proximal large muscles which is an established risk 
factor for rapid, severe envenomation syndrome and initially all were treated with higher than usual doses 
of FabAV. Despite their blatant coagulopathy, hemorrhage to include several invasive procedures was 
minimal. The acute envenomation syndrome had been rapidlycontrolled in all five cases in the first 6-12 
hours of care using typical bolus therapy.  Our hematology service was not frequently consulted until the 
defibrinogenation recurrence syndrome became manifest and our hematologic experience was requested.   
None experienced significant hemorrhage.  Additionally, we do not encounter durable or meaningful 
thrombocytopenia in Eastern diamondback rattlesnakes envenomation either initially or at recurrence, 
although the rattlesnake species encountered by patients reported Bush et al (10) in the Western US 
produce more thrombocytopenia yet less severe hypofibrinogenemia than we experience with bites from 
the Eastern diamondback rattlesnakes. (3,4) 
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Table 1 Case Summaries 
 Case 1 Case 2 Case 3 Case 4 Case 5 
Age/Sex 70 M 20 M 12 M 19M 50M 
Bite site Calf Ankle Thigh Thigh Proximal arm 
Bleeding None Minimal oozing at 
PICC line insertion 
site  
Large thigh 
hematoma 
Minimal oozing from 
bite site knife wound 
Minimal oozing from 
cricothyroidotomy site 
Initial studies 
   PT, secs 
   PTT, secs 
   Fibrinogen 
level, mg/dL 
   Platelet count, 
in 1000s 
 
19.2 
30 
<35 
39 
 
>150 
>240 
<35 
39 
 
>50 
>240 
<35 
216 
 
34 
49 
<35 
225 
 
>150 
>240 
<35 
20 
Initial treatment 
   Total # vials 
   Over # days 
   Fibrinogen 
level, mg/dL 
      at end of 
treatment 
 
32 
3 
248 
 
29 
3 
250 
 
54 
8 
190 
 
23 
2 
200 
 
43 
6 
110 
Interval till 
recurrence 
   Days 
 
  Fibrinogen 
level, mg/dL 
      at 
recurrence 
 
3 
 
<35 
 
2 
 
<35 
 
2 
 
38 
 
+1Q12H x 2 with no 
recurrence 
N/A 
 
1 
 
110 
Recurrence 
treatment 
   Total # vials 
   Over # days 
   Fibrinogen 
level, mg/dL 
      at 
termination 
 
20 
5 
500 
 
8 
3 
210 
 
6 
3 
140 
 
N/A 
N/A 
N/A 
 
6 
3 
361 
 
Follow-up at 2-4 
weeks 
   Fibrinogen 
levels, mg/dL 
   Platelets 
 
140 
“Normal” 
 
151 
“Normal” 
 
125 
“Normal” 
 
“Normal” 
“Normal” 
 
“Normal” 
“Normal” 
 
 
 
 
 
 
 
 
Figure 1 Typical improvement with 
early treatment followed by recurrent 
defibrogenation days later 
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Conclusion 
These data are consistent with the hypothesis that hematologic recurrence syndrome seems easily 
controlled with low-dose constant infusion of FabAV over a 2-3 day period.  Thus we agree with Bush 
and colleagues (10) that this is a feasible approach.  Additionally, this approach seems to decrease total 
FabAV exposure.  Obviously another interpretation of these data could be that all these patients were 
almost at a point in their hospitalizations that they were near spontaneous cure, even without any further 
administration of FabAV.   
This small titered-to-effect dose appears safe, especially when compared to the previously used method 
which reflects “starting over” using large and frequently administered bolus therapy with FabAV. Thus 
we have saved an estimated 20-40 extra vials of FabAV per patient, as well as an uncertain amount of 
blood products,particularly FFP and cryoprecipitate, which we did not employ in any of these patients for 
this late recurrence syndrome. We agree with Bush et al (10) that we cannot claimsuperiority or even 
causation in an evidence-based manner without a randomized controlled trial.  Reports of further 
experience in this area by othertreaters are warranted. 
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